Skip to main content
Funded Studies

Identification of Small-molecule Stabilizers of DJ-1: Biophysical and Cellular Validation

Objective/Rationale:
The goal of our project is to develop an approach to treat PD by stabilizing wild-type dimeric DJ-1 with a small molecule. We hypothesize that this approach will lead to an elevated level of DJ-1 in vivo under PD disease conditions. Small molecule binding could directly interfere with DJ-1 superfluous oxidation by preventing over-oxidation of Cys106 of DJ-1, as proposed by Ariga and co-workers (J Neurochem 2008, 10, 1471). Alternatively, a small molecule could also mitigate the harmful effects of superfluous oxidation via thermodynamic stabilization of the DJ-1 homodimer when several of its Cys and Met amino acid are already over-oxidized (Rochet and co-workers; Biochemistry 2007, 46, 5776). Our approach enables the discovery of small molecules with either or both mechanisms of action and therefore offers a novel way forward to develop a disease modifying therapeutic for PD.

Project Description:
Recently, we carried out a unique biophysics-based, high-throughput screen to identify novel scaffolds of small-molecule binders to native DJ-1. This grant will enable us to (1) determine the affinity of hit compounds to DJ-1, (2) asses their ability to stabilize native and/or oxidized DJ-1 dimer, and (3) to prevent DJ-1 dimer oxidation and de-stabilization via binding to the protein. Furthermore, selected small-molecule DJ-1 stabilizers will be test for their ability to rescue dopaminergic neurons from rotenone- (oxidative) and alpha-synuclein-mediated toxicity.

Relevance to Diagnosis/Treatment of Parkinson’s Disease:
Homozygous mutations in the DJ-1 gene have been linked to early-onset of PD. Under oxidizing conditions, DJ-1 can undergo superfluous oxidation of several Cys and Met residues, which may lead to DJ-1 inactivity as a result of structural destabilization. The downregulation of endogenous DJ-1 sensitizes neurons to cell death induced by oxidative insults, whereas elevated levels of wild-type, but not mutant, DJ-1 protect neurons from oxidative stress and other PD related insults. DJ-1 knockout pre-clinical models show nigrostriatal dopaminergic deficits and are hypersensitive to the toxic effects of MPTP. Our drug discovery approach to DJ-1 is designed for to the discovery of small molecules, which could result an elevated level of DJ-1 in vivo under PD conditions.

Anticipated Outcome:
Our proposed studies can (1) result in the discovery of functional small molecule ligands of DJ-1; (2) enable us to select different chemical scaffolds targeting DJ-1 with elucidated mechanism of action for hit/lead optimization; and (3) provide small-molecule probes to explore DJ-1 function and loss of function as related to PD in different in vivo models.
 


Researchers

  • Gergely Toth, PhD

    Mclean, VA United States


  • Jean-Christophe Rochet, PhD

    West Lafayette, IN United States


Discover More Grants

Within the Same Program

Within the Same Funding Year

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.